BRAF (T599_V600insT)

BRAF · Variant type: indel · HGVS: p.T599_V600insT

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Encorafenib	99.9%	0.1%	98.50
2	Dabrafenib	99.1%	0.9%	94.74
3	Ripretinib	98.6%	1.4%	92.95
4	Ponatinib	98.1%	1.9%	78.23
5	Regorafenib	96.1%	3.9%	95.99
6	Sorafenib	95.8%	4.3%	96.72
7	Dasatinib	89.2%	10.8%	87.97
8	Apatinib	75.9%	24.1%	97.73
9	Vemurafenib	75.8%	24.2%	96.49
10	Nilotinib	68.5%	31.5%	96.49
11	Erdafitinib	48.5%	51.5%	95.71
12	Pacritinib	40.9%	59.1%	88.64
13	Tivozanib	36.8%	63.2%	92.42
14	Gedatolisib	35.8%	64.2%	99.75
15	Canertinib	34.7%	65.3%	96.49
16	Umbralisib	31.2%	68.8%	98.74
17	Pazopanib	30.8%	69.2%	97.49
18	Dacomitinib	24.9%	75.1%	97.99
19	Upadacitinib	24.4%	75.6%	97.98
20	Rabusertib	21.9%	78.1%	98.74
21	Repotrectinib	19.9%	80.1%	84.21
22	Gefitinib	18.4%	81.6%	99.25
23	Afatinib	17.2%	82.8%	98.50
24	Vandetanib	16.3%	83.7%	95.74
25	Crizotinib	13.4%	86.6%	91.39

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Encorafenib	99.9%	98.0%	+1.9%
Dabrafenib	99.1%	98.3%	+0.7%
Ripretinib	98.6%	100.0%	-1.4%
Ponatinib	98.1%	99.4%	-1.3%
Regorafenib	96.1%	98.3%	-2.2%
Sorafenib	95.8%	98.5%	-2.8%
Dasatinib	89.2%	80.6%	+8.6%
Apatinib	75.9%	94.1%	-18.2%
Vemurafenib	75.8%	92.8%	-17.0%
Nilotinib	68.5%	85.8%	-17.3%
Erdafitinib	48.5%	54.1%	-5.6%
Pacritinib	40.9%	58.5%	-17.6%
Tivozanib	36.8%	41.8%	-5.0%
Gedatolisib	35.8%	56.5%	-20.7%
Canertinib	34.7%	40.7%	-5.9%
Umbralisib	31.2%	65.3%	-34.1%
Pazopanib	30.8%	79.3%	-48.6%
Dacomitinib	24.9%	46.6%	-21.7%
Upadacitinib	24.4%	49.6%	-25.2%
Rabusertib	21.9%	41.1%	-19.1%
Repotrectinib	19.9%	—	—
Gefitinib	18.4%	—	—
Afatinib	17.2%	—	—
Vandetanib	16.3%	—	—
Crizotinib	13.4%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.0ms